Condition
Anal Margin Squamous Cell Carcinoma
Total Trials
3
Recruiting
0
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 2 (2)
P 3 (1)
Trial Status
Active Not Recruiting3
Clinical Trials (3)
Showing 3 of 3 trials
NCT03233711Phase 3Active Not Recruiting
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT04929028Phase 2Active Not Recruiting
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
NCT04166318Phase 2Active Not Recruiting
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
Showing all 3 trials